SureTrader Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, bearspread
Search This Board:
Last Post: 7/13/2016 11:41:24 AM - Followers: 187 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#11769   Ask stacked at 30 million now ar .0004. Ben Axeman 07/13/16 11:41:23 AM
#11768   A more good strategy on the business is stockscheers 07/13/16 02:34:24 AM
#11767   Down....Down. Nothing new on the news front imo Axeman 07/11/16 01:06:03 PM
#11766   Watching this for market direction. stockscheers 07/11/16 04:59:15 AM
#11765   LOL $7 paint trade with 10 million on onthegreen 07/08/16 03:33:27 PM
#11764   More 8k's on the way!!! onthegreen 07/08/16 01:37:15 PM
#11763   Look at the past and tell me otherwise Axeman 07/08/16 11:40:56 AM
#11762   How do you know that "Conversions will NEVER stoprun 07/08/16 11:38:44 AM
#11761   Unfortunately Ben has continued to destroy value with Axeman 07/08/16 11:23:52 AM
#11760   hopefully breakout of the consolidation range for real. stockscheers 07/07/16 04:56:43 AM
#11759   Ben will Reverse it again after he dumps onthegreen 07/05/16 08:49:00 AM
#11758   What's the worst that could happen here? stockscheers 07/05/16 05:01:10 AM
#11757   RCHA = CHINESE SHARE SELLING SCAM. THAT IS onthegreen 07/01/16 04:51:51 PM
#11756   RCHA - I feel Rich Pharma requires a sidsaldanha 07/01/16 09:55:10 AM
#11755   Needs to build up some momentum though. This stockscheers 07/01/16 04:27:32 AM
#11754   LMFAO! ANOTHER 8K TODAY! BEN DUMPING THEM AS onthegreen 06/30/16 02:42:11 PM
#11753   Entry of judgment, confession in default. Long-vestor 06/30/16 10:27:46 AM
#11752   Man this thing is a piece of crap pearlwsz7 06/28/16 06:24:51 PM
#11751   New OS 426,099,255 headed to a billion. Ben Axeman 06/28/16 01:33:00 AM
#11750   LMFAO! Another 8k! 60M @.0002. Ben making a onthegreen 06/27/16 07:05:02 PM
#11749   Wow been watching this one for a while... otclad 06/24/16 12:48:43 PM
#11747   Ben's ATM machine on Full Power again today. onthegreen 06/24/16 12:21:35 PM
#11746   Rich has no money so toxic is the Axeman 06/24/16 11:33:10 AM
#11745   RCHA - Investors want progression, not decline. The sidsaldanha 06/24/16 11:32:08 AM
#11744   .0003 Ben is in trouble. Scam indeed and Axeman 06/24/16 11:29:26 AM
#11743   LOL. Chinese share selling scam! onthegreen 06/23/16 03:50:10 PM
#11742   Yep, I can't even sell my shares Rookiemove 06/23/16 12:27:51 PM
#11741   Welcome to the club. Just look at the Axeman 06/23/16 11:24:32 AM
#11740   RCHA - Rich Pharma is NOT forthcoming with sidsaldanha 06/23/16 10:38:23 AM
#11739   yupp, it think it is still long core stockscheers 06/23/16 04:32:03 AM
#11738   A/S raised to 4 Billion a few weeks onthegreen 06/22/16 02:40:42 PM
#11737   RCHA - If that were the case, sidsaldanha 06/22/16 02:20:41 PM
#11736   LOL, wasn't this @ 0013 last week? onthegreen 06/22/16 02:12:13 PM
#11735   RCHA - Axeman, I am starting to see sidsaldanha 06/22/16 02:09:26 PM
#11734   Here comes .0004. TOXIC DEATH SPIRAL FINANCING BY Axeman 06/22/16 02:07:18 PM
#11733   Selling will be mainly toxic just read the 8ks. Axeman 06/22/16 11:54:17 AM
#11732   RCHA - I feel the sell off bleeding sidsaldanha 06/22/16 11:49:21 AM
#11731   LMAO. Chinese Share Selling Scam. Many 8k's onthegreen 06/22/16 10:56:18 AM
#11730   RCHA - THe real incentive here is to sidsaldanha 06/22/16 10:32:43 AM
#11729   Recent conversions @ .0001, so Ben and his onthegreen 06/21/16 02:21:50 PM
#11728   Just know that Ben doesn't care about his Axeman 06/21/16 01:40:21 PM
#11727   RCHA - Considering the positive steps of RICH sidsaldanha 06/21/16 01:30:23 PM
#11726   Once a pig always a pig and the Axeman 06/21/16 11:34:53 AM
#11725   RCHA - As of the DEF 14C filed sidsaldanha 06/21/16 11:26:20 AM
#11724   Upcoming 8k will be massive!!! Guaranteed! onthegreen 06/21/16 11:15:52 AM
#11723   The bid is getting dumped on and going Axeman 06/21/16 11:02:21 AM
#11722   RCHA - The ASK is thin and those sidsaldanha 06/21/16 10:46:14 AM
#11721   It's all about sharing selling to stay afloat Axeman 06/21/16 10:42:59 AM
#11720   RCHA - The NEW PR states "Additional agreement". sidsaldanha 06/21/16 10:35:02 AM
#11719   Fluff PR of old again. Nothing new just Axeman 06/21/16 10:26:25 AM